IRhythm Technologies Inc. has announced the publication of a large-scale clinical study in the journal Heart Rhythm, featuring real-world data from more than 1.1 million patients who used the company's Zio® long-term continuous monitoring (LTCM) service. The study found that short-term (24-48-hour) monitoring may miss actionable arrhythmias, even in patients reporting daily symptoms, and that patient-reported symptoms were infrequently associated with arrhythmia events. These results highlight the potential value of long-term continuous monitoring. In addition, data from over 742,000 patients were presented at the American Heart Association (AHA) Scientific Sessions 2025, demonstrating that at-home self-application and activation of Zio 14-day patch-based LTCM devices achieved high compliance, strong engagement, and data quality comparable to in-clinic application. Further analyses presented at AHA 2025 provided expanded insights into CKM/CKD risk and supported earlier arrhythmia detection in at-risk populations. IRhythm's ongoing collaboration with Lucem Health was also noted, aiming to combine ECG monitoring with AI-powered risk stratification to more precisely identify individuals at risk for arrhythmias. Early pilot testing from this collaboration suggests potential improvements in targeting at-risk populations and enabling earlier clinical engagement.